...
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >An Open‐Label Discontinuation Trial of Long‐Term, Off‐Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure
【24h】

An Open‐Label Discontinuation Trial of Long‐Term, Off‐Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure

机译:在具有智力残疾人的人们中,长期脱核抗精神病药的开放标签停止试验:成功和失败的决定因素

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Although physicians are aware of the risks of prescribing long‐term off‐label antipsychotics in people with intellectual disability, attempts to discontinue often fail. This study aimed to identify potential determinants of successful and failed discontinuation. Long‐term off‐label antipsychotics were tapered in 14 weeks, with 12.5% of baseline dose every 2 weeks. Participants living in facilities offered by intellectual disability service providers, ≥6 years, with an IQ 70 were eligible to discontinue antipsychotic use, as judged by their physicians. The primary outcome was achievement of complete discontinuation at 16 weeks; changes in the Aberrant Behavior Checklist (ABC) and its 5 subscales were secondary outcomes. Potential determinants of the success or failure in discontinuing antipsychotics were psychotropic drug use and participants’ living circumstances, medical health conditions, and severity of behavioral symptoms and neurologic side effects. Of 499 eligible clients, 129 were recruited. Reasons for client non‐participation were clinician concerns that discontinuation might increase challenging behaviors and changes in clients’ environment. Of the 129 participants, 61% had completely discontinued antipsychotics at 16 weeks, 46% at 28 weeks, and 40% at 40 weeks. ABC total scores increased in 49% of participants with unsuccessful discontinuation at 16 weeks. Autism, higher dose of antipsychotic drug, higher ABC and akathisia scores, and more‐frequent worsening of health during discontinuation were associated with a lower incidence of complete discontinuation. Thus, in a selected sample of participants whom responsible clinicians had deemed discontinuation of antipsychotics could be attempted, 40% had achieved and maintained discontinuation at end of follow‐up. Physicians should try to address patients’ conditions that may hamper discontinuation.
机译:摘要虽然医生意识到具有智力残疾人的人们在人们中规定长期非抗标签的抗精神病学的风险,但试图停止经常失败。本研究旨在识别成功和失败失败的潜在决定因素。长期脱蛋白抗精神病药在14周内逐渐变细,每2周为12.5%的基线剂量。居住在智力残疾服务提供商提供的设施的参与者,≥6年,具有IQ< 70有资格停止抗精神用,由他们的医生判断。主要结果是在16周内实现完全停药;异常行为核对表(ABC)的变化及其5分量是二次结果。停止抗精神病药成功或失败的潜在决定因素是精神药物使用,参与者的生活环境,医疗保健条件,以及行为症状的严重程度和神经系统副作用。 499个符合条件的客户,129个被招募。客户不参与的原因是临床医生担心,停药可能会增加挑战性行为和客户环境的变化。在129名参与者中,61%在16周内完全停止了抗精神病药,28周,46%,40%。 ABC总分数在49%的参与者中增加了49%,在16周内停止不成功。自闭症,较高剂量的抗精神病药物,更高的ABC和Akathisia分数,在停止期间的健康状况越来越恶化与完全停药的较低发病率较低。因此,在负责临床医生被视为停止抗精神病药的参与者的选定样本中,可以尝试,40%在随访结束时取得了达到的停药。医生应尽量解决可能妨碍停止的病人的条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号